CN102309675B - Application of Chinese medicine composition in preparing medicines for treating sick sinus syndrome - Google Patents
Application of Chinese medicine composition in preparing medicines for treating sick sinus syndrome Download PDFInfo
- Publication number
- CN102309675B CN102309675B CN2011102745829A CN201110274582A CN102309675B CN 102309675 B CN102309675 B CN 102309675B CN 2011102745829 A CN2011102745829 A CN 2011102745829A CN 201110274582 A CN201110274582 A CN 201110274582A CN 102309675 B CN102309675 B CN 102309675B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- medicine composition
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides an application of a Chinese medicine composition in preparing medicines for treating sick sinus syndrome. The Chinese medicine composition comprises ginseng, dwarf lilyturf root, Cornus officinalis, radix salvia miltiorrhiza, fried spine date seed, parasitic loranthus, red paeony root, ground beetle, Nardostachyos Root and Rhizome, and other traditional Chinese medicines. Clinical experiments prove that the Chinese medicine composition has substantial clinic curative effect for treating sick sinus syndrome.
Description
The present patent application is dividing an application of No. 200810054809.7 patent application.The original application applying date is 2008.4.18 day; Application number is: 200810054809.7; Denomination of invention is: the application of a kind of Chinese medicine composition in preparation treatment bradyarrhythmia medicine.
Technical field
The present invention relates to the application of a kind of Chinese medicine composition in preparation treatment slow arrhythmia medicine, belong to the Chinese herbal medicine application.
Background technology
Arrhythmia (cardiac arrhythmia) refers to rhythm of the heart origin position, cardiac frequency and the rhythm and pace of moving things and conduction of impulse etc., and each is unusual.The implication of the word such as " cardiac arrhythmia " or " arrhythmia " biases toward the not normal of the expression rhythm and pace of moving things, and arrhythmia not only comprises the rhythm and pace of moving things but also comprise the unusual of frequency, and more definite and appropriate, arrhythmia has a strong impact on the blood-pumping function of heart, in time treatment.
Arrhythmia can be divided into sinus arrhythmia, atrial arrhythmia, atrioventricular junction arrhythmia, ventricular arrhythmia and heart block according to the arrhythmia happening part; And according to the speed of the arrhythmia rhythm of the heart, arrhythmia can be divided into Quick-type and slow arrhythmia.[the 2nd edition P172-212 in Ye Rengao internal medicine People's Health Publisher October in 1984].
Bradyarrhythmia is impaired sinus node failure, the pacing function obstacle of causing of sinus-node self-activity that is caused by many reasons, or because causing conduction function, sinuatrial node, atrium, atrioventricular node and atrioventricular bundle pathological changes reduce, make due to the crackled with excitement of sinuatrial node can not pass down as scheduled, its Clinical symptoms be the rhythm of the heart slowly and the hemodynamics change.Slow arrhythmia comprises conduction block in sinus bradycardia, sinoatrial block, sinus standstill, sick sinus syndrome, the room, atrioventricular block and intraventricular block etc.Clinically often show as that Consciousness Disturbances Following is crossed in dizziness, blindness, cardiopalmus, one, the symptom such as faint, severe patient produces cardiogenic syncope, even can cause death; Clinical pulse condition shows as slow pulse more and ties generation.Wherein heart rate slowly and rule take sinus bradycardia, 2: 1 or 3: 1 or dissociation or sino atrial block, the atrioventricular junction rhythm of the heart as common.Slow and irregular person merges irregular antrum or Atrioventricular Conduction as common take atrial fibrillation, sinus bradycardia companion arrhythmia, sinus rhythm.
Patent ZL02146572.X discloses a kind of pharmaceutical composition for the treatment of Coronary heart disease ventricular early throb and preparation method thereof, and present patent application quotes in full the content that patent ZL02146572.X puts down in writing.The application of unexposed this pharmaceutical composition of this patent in preparation treatment slow arrhythmia medicine, and application only limits to the treatment of Coronary heart disease ventricular early throb, and the present invention has done further research on the basis of this patented technology.Confirm that Chinese medicine composition of the present invention has significant clinical efficacy to slow arrhythmia.
Summary of the invention
The purpose of this invention is to provide a kind of Chinese medicine composition and restrain application in the not normal medicine at the slow sexual type of preparation treatment.
The invention provides a kind of Chinese medicine composition and restrain application in the not normal medicine at the slow sexual type of preparation treatment, it is characterized in that this Chinese medicine composition is made by the crude drug of following weight portion:
Radix Ginseng 45-180 part, Radix Ophiopogonis 50-200 part, Fructus Corni 125-450 part, Radix Salviae Miltiorrhizae 125-450 part, Semen Ziziphi Spinosae (parched) 95-400 part, Herba Taxilli 95-400 part, Radix Paeoniae Rubra 45-200 part, Eupolyphaga Seu Steleophaga 35-150 part, Radix Et Rhizoma Nardostachyos 45-200 part, Rhizoma Coptidis 25-90 part, Fructus Schisandrae Sphenantherae 35-150 part, Os Draconis 75-300 part.
The weight ratio of Chinese medicine composition Raw medicine of the present invention is preferably:
89 parts of Radix Ginsengs, 112 parts of Radix Ophiopogonis, 224 parts of Fructus Corni, 224 parts of Radix Salviae Miltiorrhizaes, 186 parts of Semen Ziziphi Spinosae (parched)s, 186 parts of Herba Taxillis, 89 parts of Radix Paeoniae Rubra, 75 parts of Eupolyphaga Seu Steleophagas, 89 parts of Radix Et Rhizoma Nardostachyos, 45 parts of Rhizoma Coptidis, 67 parts of Fructus Schisandrae Sphenantheraes, 149 parts of Os Draconis.
The weight ratio of Chinese medicine composition Raw medicine of the present invention also is preferably:
45 parts of Radix Ginsengs, 112 parts of Radix Ophiopogonis, 224 parts of Fructus Corni, 225 parts of Radix Salviae Miltiorrhizaes, 186 parts of Semen Ziziphi Spinosae (parched)s, 186 parts of Herba Taxillis, 89 parts of Radix Paeoniae Rubra, 45 parts of Radix Et Rhizoma Nardostachyos, 35 parts of Eupolyphaga Seu Steleophagas, 45 parts of Rhizoma Coptidis, 67 parts of Fructus Schisandrae Sphenantheraes, 149 parts of Os Draconis.
The weight ratio of Chinese medicine composition Raw medicine of the present invention also is preferably:
90 parts of Radix Ginsengs, 135 parts of Radix Ophiopogonis, 270 parts of Fructus Corni, 200 parts of Radix Salviae Miltiorrhizaes, 150 parts of Semen Ziziphi Spinosae (parched)s, 150 parts of Herba Taxillis, 100 parts of Radix Paeoniae Rubra, 100 parts of Eupolyphaga Seu Steleophagas, 95 parts of Radix Et Rhizoma Nardostachyos, 60 parts of Rhizoma Coptidis, 75 parts of Fructus Schisandrae Sphenantheraes, 150 parts of Os Draconis.
In the application of the present invention, the active component of this Chinese medicine composition is made by the following step:
A) people participates in 70% alcohol reflux three times, and merge extractive liquid, filters, and is concentrated, oven dry, the fine powder that is ground into;
B) Fructus Schisandrae Sphenantherae, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos add 70% alcohol reflux 3 times jointly, and merge extractive liquid, filters, concentrated extractum;
C) fine powder that is broken into of Eupolyph aga sinesis Walker;
D) Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis decoct with water 2 times, merge extractive liquid,, concentrated extractum.
E) with step b) and d) gained extractum merge, add step c) fine drug powder of gained, oven dry is ground into fine powder, adds a) gained fine drug powder of step, mixing namely gets this Chinese medicine composition active component.
In the application of the present invention, described Chinese medicine composition is capsule, tablet, electuary, a kind of in powder or the oral liquid formulations, for above-mentioned dosage form can be realized, need when these dosage forms of preparation, to add the acceptable adjuvant of pharmacy, for example: filler, disintegrating agent, lubricant, suspending agent, binding agent, sweeting agent, correctives, antiseptic etc., filler comprises: starch, pregelatinized Starch, lactose, mannitol, chitin, microcrystalline Cellulose, sucrose etc., disintegrating agent comprises: starch, pregelatinized Starch, microcrystalline Cellulose, carboxymethyl starch sodium, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose etc., lubricant comprises: magnesium stearate, sodium lauryl sulphate, Pulvis Talci, silicon dioxide etc., suspending agent comprises: polyvinylpyrrolidone, microcrystalline Cellulose, sucrose, agar, hydroxypropyl emthylcellulose etc., binding agent comprises, starch slurry, polyvinylpyrrolidone, hydroxypropyl emthylcellulose etc., sweeting agent comprises: saccharin sodium, Aspartane, sucrose, cyclamate, enoxolone etc., correctives comprises: sweeting agent and various essence, and antiseptic comprises: parabens, benzoic acid, sodium benzoate, sorbic acid and its esters, benzalkonium bromide, the acetic acid chloroethene is fixed, the Folium eucalypti globueli (Eucalyptus globulus Labill.) wet goods.
During the present invention used, described slow arrhythmia was preferably sinus bradycardia.
During the present invention used, described slow arrhythmia also was preferably sinoatrial block.
During the present invention used, described slow arrhythmia also was preferably sick sinus syndrome.
During the present invention used, described slow arrhythmia also was preferably conduction block in the room, atrioventricular block or intraventricular block.。
The consumption of Chinese medicine composition of the present invention by active component crude drug gross weight, is 7-28 gram/day, but takes every day once, preferably divides and takes for 2-4 time.
The specific embodiment
Following embodiment is used for illustrating the preparation of Chinese medicine composition of the present invention, but it can not consist of any restriction to scope of the present invention.
Embodiment 1
For the ease of the application of this traditional Chinese medicine composition for treating slow arrhythmia, this Chinese medicine composition is prepared as capsule
Prescription:
Radix Ginseng 89g 112g Radix Ophiopogonis Fructus Corni 224g Radix Salviae Miltiorrhizae 224g
Semen Ziziphi Spinosae (parched) 186g Herba Taxilli 186g Radix Paeoniae Rubra 89g Eupolyphaga Seu Steleophaga 75g
Radix Et Rhizoma Nardostachyos 89g Rhizoma Coptidis 45g Fructus Schisandrae Sphenantherae 67g Os Draconis 149g
Preparation method:
A) in the above-mentioned prescription, Radix Ginseng is with 70% alcohol reflux three times, and 3 hours for the first time, each 2 hours later on, merge extractive liquid, filtered, and Recycled ethanol is concentrated, and oven dry is ground into fine powder, and is for subsequent use;
B) in the above-mentioned prescription, Fructus Schisandrae Sphenantherae, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos are with 70% alcohol reflux three times, and merge extractive liquid, filters, Recycled ethanol, and the concentrated extractum that to get, for subsequent use;
C) in the above-mentioned prescription, Eupolyph aga sinesis Walker is broken into fine powder, and is for subsequent use;
D) in the above-mentioned prescription, Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis decoct with water secondary, and merge extractive liquid, filters, and the extracting solution of filtrate and Fructus Schisandrae Sphenantherae etc. merges, and concentrates to get extractum, and is for subsequent use;
E) with step b) and d) gained extractum merge, add step c) the fine drug powder oven dry of gained, be ground into fine powder, add a) gained fine drug powder of step, mixing, 1000 capsules of packing into.
Usage and consumption: oral.One time 2～4,3 times on the one.
Test example
For illustrating the activity of traditional Chinese medicine composition for treating slow arrhythmia of the present invention, use the capsule (hereinafter referred to as medicine of the present invention) that makes by above-described embodiment 1 method to carry out following clinical trial.
1 data and method
1.1 the physical data all cases all is selected from Hebei Yi Ling Patients during Hospital Ward, amounts to 74 examples, is divided at random treatment group and matched group, every group of 37 examples.Treatment group man 20 examples, women 17 examples, mean age (55.23 ± 7.05) year; Average course of disease (7.6 ± 2.5) year; Types of arrhythmia: sinus bradycardia 12 examples, sinus arrest 4 examples, sick sinus syndrome 8 examples, II degree sinoatrial block 8 examples, II Aminophyline 5 examples; Protopathy: coronary heart disease 20 examples, viral myocarditis 8 examples, cardiomyopathy 4 examples, hypertensive heart disease 5 examples.Matched group man 21 examples, women 16 examples; Year mean age (56.02 ± 8.11); Average course of disease (8.2 ± 2.3) year; Types of arrhythmia: sinus bradycardia 12 examples, sinus arrest 5 examples, sick sinus syndrome 7 examples, II degree sinoatrial block 9 examples, II Aminophyline 4 examples; Protopathy: coronary heart disease 19 examples, viral myocarditis 9 examples, cardiomyopathy 5 examples, hypertensive heart disease 4 examples.Process there was no significant difference (P＞0.05) learning by statistics aspect sex, age, the course of disease and the ill-distribution for two groups, have comparability.
1.2 case is selected inclusion criteria: 40～70 years old (1) age, male or female; (2) reference " cardiovascular diseases's Differential Diagnosis " [the Marvin's pearl. cardiovascular diseases's Differential Diagnosis (M). Nanjing: Jiangsu science tech publishing house, 1992:97～98] diagnostic method, electrocardiographic diagnosis: heart rate≤50 time/min, the total heart rate of 24h ambulatory electrocardiogram (Holter)≤75000 times, average heart rate≤50 time/min.Exclusion standard: (1) merges the primary diseases such as cardiovascular, liver, kidney and hemopoietic system; (2) allergic constitution has allergies person to multi-medicament; (3) trimester of pregnancy or women breast-feeding their children.In addition, also stop this research if the one of following situations appears in selected patient: the serious adverse reaction person occurs in (1); (2) serious organ failure person appears.
1.3 the Therapeutic Method matched group adopts atropine treatment, 0.3g/ time, 3 times/days.Treatment group adds on matched group medication basis uses Drug therapy of the present invention, and 4 tablets/times, 3 times/days.Be for 4 weeks the course for the treatment of.Other arrhythmia Chinese and western drugses of stopping using simultaneously.
1.4 observation index: observe treatment front and back 24 hourly average hearts rate, fast and the slowest heart rate number of times.
1.5 curative effect determinate standard: take 1997 Shanghai " therapy of combining Chinese and Western medicine coronary heart diseases and angina pectoris and arrhythmia " forum " angina pectoris and arrhythmia evaluation criteria " as criterion of therapeutical effect.The recovery from illness: clinical symptom disappearance, electrocardiogram are roughly normal, Holter (dynamic ecg) show heart rate (sinus rhythm) through be everlasting 60 times/more than the min; Produce effects: clinical cardinal symptom disappears, and electrocardiogram obviously improves, and Holter shows 24h average heart rate (sinus rhythm) than treating front 〉=10 times/min; Effectively: clinical cardinal symptom partly disappears, and electrocardiogram is treated front improvement, and Holter shows before 24h average heart rate (sinus rhythm) is than treatment increases 〉=5 times/min; Invalid: clinical symptoms and electrocardiogram are without improvement, and Holter shows that 24h average heart rate (sinus rhythm) is without increasing or increase＜5 times/min.
1.6 statistical procedures adopts the SPSS13.0 statistical software to carry out date processing, measurement data is with mean ± standard deviation
The t check is adopted in expression, and enumeration data adopts x
2Check.
2 results
2.1 Clinical efficacy comparison by statistics, treatment group patient's total effective rate is apparently higher than matched group (P＜0.05).The results are shown in Table 1.
Table 1 liang group patient clinical curative effect is (%) relatively
Annotate: * and # be x relatively
2=4.57, P＜0.05.
2.2 treatment front and back Holter situation by statistics, treatment group 24 hourly average hearts rate, fast and the slowest heart rate time number average are apparently higher than matched group (P＜0.05).The results are shown in Table 2.
The comparison of Holter situation before and after the table 2 liang group patient treatment
Annotate: * and # be P＜0.05 relatively; * and ## be P＜0.05 relatively;
With ◆ compare P＜0.05.
3 conclusions
This research is on the basis of doctor trained in Western medicine conventional therapy, add Drug therapy of the present invention, all be better than simple western medical treatment at aspects such as improving clinical efficacy, increase by 24 hourly average hearts rate, the fastest and the slowest heart rate number of times, fully proved invention medicine has significant clinical efficacy to slow arrhythmia.
Claims (6)
1. the application of Chinese medicine composition in preparation treatment sick sinus syndrome medicine is characterized in that this Chinese medicine composition is made by the crude drug of following weight portion:
Radix Ginseng 45-180 part, Radix Ophiopogonis 50-200 part, Fructus Corni 125-450 part, Radix Salviae Miltiorrhizae 125-450 part, Semen Ziziphi Spinosae (parched) 95-400 part, Herba Taxilli 95-400 part, Radix Paeoniae Rubra 45-200 part, Eupolyphaga Seu Steleophaga 35-150 part, Radix Et Rhizoma Nardostachyos 45-200 part, Rhizoma Coptidis 25-90 part, Fructus Schisandrae Sphenantherae 35-150 part, Os Draconis 75-300 part.
2. application as claimed in claim 1 is characterized in that, this Chinese medicine composition is made by the crude drug of following weight portion:
89 parts of Radix Ginsengs, 112 parts of Radix Ophiopogonis, 224 parts of Fructus Corni, 224 parts of Radix Salviae Miltiorrhizaes, 186 parts of Semen Ziziphi Spinosae (parched)s, 186 parts of Herba Taxillis, 89 parts of Radix Paeoniae Rubra, 75 parts of Eupolyphaga Seu Steleophagas, 89 parts of Radix Et Rhizoma Nardostachyos, 45 parts of Rhizoma Coptidis, 67 parts of Fructus Schisandrae Sphenantheraes, 149 parts of Os Draconis.
3. application as claimed in claim 1 is characterized in that, this Chinese medicine composition is made by the crude drug of following weight portion:
45 parts of Radix Ginsengs, 112 parts of Radix Ophiopogonis, 224 parts of Fructus Corni, 225 parts of Radix Salviae Miltiorrhizaes, 186 parts of Semen Ziziphi Spinosae (parched)s, 186 parts of Herba Taxillis, 89 parts of Radix Paeoniae Rubra, 45 parts of Radix Et Rhizoma Nardostachyos, 35 parts of Eupolyphaga Seu Steleophagas, 45 parts of Rhizoma Coptidis, 67 parts of Fructus Schisandrae Sphenantheraes, 149 parts of Os Draconis.
4. application as claimed in claim 1 is characterized in that, this Chinese medicine composition is made by the crude drug of following weight portion:
90 parts of Radix Ginsengs, 135 parts of Radix Ophiopogonis, 270 parts of Fructus Corni, 200 parts of Radix Salviae Miltiorrhizaes, 150 parts of Semen Ziziphi Spinosae (parched)s, 150 parts of Herba Taxillis, 100 parts of Radix Paeoniae Rubra, 100 parts of Eupolyphaga Seu Steleophagas, 95 parts of Radix Et Rhizoma Nardostachyos, 60 parts of Rhizoma Coptidis, 75 parts of Fructus Schisandrae Sphenantheraes, 150 parts of Os Draconis.
5. such as the arbitrary described application of claim 1-4, it is characterized in that the active component of this Chinese medicine composition is made by the following step:
A) people participates in 70% alcohol reflux three times, and merge extractive liquid, filters, and is concentrated, oven dry, the fine powder that is ground into;
B) Fructus Schisandrae Sphenantherae, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos add 70% alcohol reflux 3 times jointly, and merge extractive liquid, filters, concentrated extractum;
C) fine powder that is broken into of Eupolyph aga sinesis Walker;
D) Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis decoct with water 2 times, merge extractive liquid,, concentrated extractum;
E) with step b) and d) gained extractum merge, add step c) fine drug powder of gained, oven dry is ground into fine powder, adds a) gained fine drug powder of step, mixing namely gets this Chinese medicine composition active component.
6. such as each described application among the claim 1-4, it is characterized in that the preparation formulation of described Chinese medicine composition is a kind of in capsule, tablet, electuary, powder or the oral liquid formulations.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102745829A CN102309675B (en) | 2008-04-18 | 2008-04-18 | Application of Chinese medicine composition in preparing medicines for treating sick sinus syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102745829A CN102309675B (en) | 2008-04-18 | 2008-04-18 | Application of Chinese medicine composition in preparing medicines for treating sick sinus syndrome |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008100548097A Division CN101559162B (en) | 2008-04-18 | 2008-04-18 | Application of traditional Chinese medicine composition in preparing medicament for curing slow arrhythmia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102309675A CN102309675A (en) | 2012-01-11 |
| CN102309675B true CN102309675B (en) | 2013-02-27 |
Family
ID=45423483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011102745829A Active CN102309675B (en) | 2008-04-18 | 2008-04-18 | Application of Chinese medicine composition in preparing medicines for treating sick sinus syndrome |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102309675B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105055846A (en) * | 2015-09-20 | 2015-11-18 | 庞群 | Sick sinus syndrome and drug for treating same |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1403148A (en) * | 2002-10-24 | 2003-03-19 | 河北以岭医药研究院有限公司 | Medicines composition for treating coronary heart disease ventricular premature beat and its prepn |
-
2008
- 2008-04-18 CN CN2011102745829A patent/CN102309675B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1403148A (en) * | 2002-10-24 | 2003-03-19 | 河北以岭医药研究院有限公司 | Medicines composition for treating coronary heart disease ventricular premature beat and its prepn |
Non-Patent Citations (1)
| Title |
|---|
| 韩晶.参松养心胶囊临症应用体会.《第三届国际络病学大会－络病学基础与临床研究》.2007,第453页第4段. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102309675A (en) | 2012-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101757409B (en) | Application of traditional Chinese medicine composition in preparation of medicines for treating silicosis | |
| CN102908513B (en) | Application of traditional Chinese medicine composition in medicine for treating arrhythmia | |
| CN102379877B (en) | Western medicinal compound for preventing or treating myocardial ischemic chronic heart failure and application thereof | |
| CN102309675B (en) | Application of Chinese medicine composition in preparing medicines for treating sick sinus syndrome | |
| CN101698050B (en) | Application of traditional Chinese medicine composite in preparing medicine treating paroxysmal atrial fibrillation | |
| CN101167838B (en) | Traditional Chinese medicinal preparation for treating coronary heart disease and angina pectoris and its preparing process | |
| CN101632783B (en) | Application of Chinese medicinal composition in preparing medicament for treating cor pulmonale | |
| CN102309674B (en) | Use of traditional Chinese drug composition in preparing drug for treating atrioventricular block | |
| CN102579804B (en) | Chinese medicine for treating stenocardia | |
| CN101559162B (en) | Application of traditional Chinese medicine composition in preparing medicament for curing slow arrhythmia | |
| CN102204956B (en) | Chinese medicinal composition used at stroke recovery period and preparation method thereof | |
| CN101559161B (en) | Application of traditional Chinese medicine composition in preparing medicament for curing tristimania | |
| CN101313990B (en) | Application of a Chinese medicinal composition in preparing medicament for treating neurosis | |
| CN106620253B (en) | Traditional Chinese medicine composition for treating bradyarrhythmia | |
| CN101590178B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating refractory premature beat of elderly patient | |
| CN103623207A (en) | Applications of traditional Chinese medicine composition in preparation of medicines used for treating chronic heart failure together with arrhythmia | |
| CN101411814B (en) | Use of Chinese medicinal composition in preparing medicament for treating intraventricular block | |
| CN101683458B (en) | Application of a traditional Chinese medicine composition in preparation of medicament for treating vertigo | |
| CN102895514B (en) | Application of Chinese medicine composition in preparing medicines for treating pulmonary heart disease | |
| CN101658568B (en) | Application of Chinese medicinal composition in preparing medicament for treating pulmonary heart disease | |
| CN105168653A (en) | Traditional Chinese medicine composition used for treating coronary heart disease | |
| CN103961429B (en) | Traditional Chinese medicine composition having effects of moving qi and invigorating blood circulation and preparation method thereof | |
| CN105267470B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating coronary heart disease | |
| CN102210806A (en) | Application of Chinese medicinal composition to preparation of medicaments for treating nonorganic heart disease arrhythmia | |
| CN103007200B (en) | Medicament for treating coronary heart disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |